GSK Acquires RAPT Therapeutics for $2.2B

Why It Matters

The stronger‑than‑expected sales and pipeline expansion signal GSK’s ability to offset upcoming patent cliffs and intensifying vaccine competition, reinforcing its growth trajectory in a crowded pharma market.

Key Takeaways

• Q1 revenue up 2% to $10.3 bn, beating forecasts
• Oncology sales jump 40% driven by Jemperli expansion
• Acquired RAPT Therapeutics for $2.2 bn, adding food‑allergy pipeline
• Patent expiry 2027 threatens dolutegravir, GSK's top HIV drug
• Shingrix sales rise 20% to $1.33 bn, facing new competitors

Pulse Analysis

GSK’s first‑quarter performance underscores the effectiveness of its specialty‑medicine strategy, with oncology and vaccine lines delivering double‑digit growth. The 40% surge in Jemperli sales, fueled by expanded endometrial‑cancer approval, illustrates how targeted immunotherapies can quickly translate into revenue. Meanwhile, the company’s flagship shingles vaccine, Shingrix, added $1.33 billion, but faces fresh competition from Pfizer/BioNTech and Moderna, prompting GSK to double‑down on pipeline innovation.

CEO Luke Miels is steering the firm toward an aggressive R&D acceleration agenda. Recent US filings for the chronic hepatitis B candidate bepirovirsen and a suite of antibody‑drug conjugates—ris‑rez for small‑cell lung cancer and mo‑rez for ovarian and endometrial cancers—highlight a focus on high‑value oncology assets. Complementary acquisitions, notably RAPT Therapeutics for $2.2 bn and 35Pharma for $950 m, broaden GSK’s reach into food‑allergy and pulmonary‑hypertension markets, diversifying its product portfolio ahead of the 2027 dolutegravir patent cliff.

Looking forward, GSK’s growth outlook hinges on delivering new products such as the long‑acting IL‑5 inhibitor Exdensur for asthma and the MASH candidate efimosfermin. Early signals show Exdensur contributing $11 million and Nucala’s COPD launch adding $630 million, reinforcing the company’s multi‑indication strategy. By aligning robust pipeline progress with strategic acquisitions, GSK aims to achieve its $52 billion sales target by 2031, positioning itself as a resilient competitor in the evolving pharmaceutical landscape.

Deal Summary

GlaxoSmithKline (GSK) completed the acquisition of RAPT Therapeutics, a company focused on food allergy treatments, in a $2.2 billion deal. The acquisition was highlighted in GSK's first‑quarter 2026 earnings update as part of its strategy to expand its specialty medicines pipeline.